Using prophylaxis with biosimilar granulocyte colony-stimulating factor can reduce the severity of neutropenia in patients with soft tissue sarcoma.
Using prophylaxis with biosimilar granulocyte colony-stimulating factor (G-CSF) can reduce the severity of neutropenia in patients with soft tissue sarcoma, according to a study published in Supportive Care in Cancer.
For both early and advanced settings in soft tissue sarcoma, anthracycline and ifosfamide-based chemotherapy is a widely used regimen, and prophylaxis with G-CSF is usually needed to reduce the severity of chemotherapy-induced neutropenia. Italian researchers set out to determine the efficacy and safety of using the biosimilar G-CSF filgrastim in these patients.
A total of 67 patients receiving biosimilar filgrastim (US: Zarxio; Europe: Zarzio), originator filgrastim (Granulokine, Neupogen), and lenograstim (Myelostim; not approved in the United States) as primary prophylaxis were analyzed. They received a total of 360 cycles of therapy and were analyzed retrospectively.
The researchers determined that biosimilar G-CSF was effective in preventing febrile neutropenia and reducing the need for hospitalization in patients with soft tissue sarcoma undergoing epirubicin and ifosfamide treatment. Febrile neutropenia occurred in 44% of patients on biosimilar filgrastim, 40% of patients on originator filgrastim, and 45.5% of patients in the lenograstim group.
Safety profiles across the 3 groups were similar. However, using biosimilar filgrastim achieved savings of €225.25 ($251.50) over originator filgrastim and €262 ($292.54) over lenograstim.
Biosimilar G-CSF “proved comparable to its reference products from both a clinical and cost-effective standpoint,” the authors concluded.
Contributor: For Complex Cases, Continuity in Acute Care Is Necessary
April 23rd 2025For patients with complex needs and social challenges like unstable housing, the hospital has become their de facto medical home—yet each visit is a fragmented restart, without continuity, context, or a clear path forward.
Read More
Higher Weight-Adjusted Waist Index Tied to Greater Mortality Risk in Patients With Osteoarthritis
April 23rd 2025Researchers consider the weight-adjusted waist index a more precise predictor of mortality risk in patients with osteoarthritis than traditional obesity measures, like body mass index.
Read More